Logo of Vectus Biosystems (ASX:VBS)Latest Vectus Biosystems (ASX:VBS) News

Page 1
Page 1 of 3

Vectus receives supportive FDA feedback for VB0004 lung fibrosis trial

Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
16 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Vectus reaches FDA pre-IND milestone as cash runway tightens

Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
29 Oct 2026

Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026

Clinical setbacks and cash shortages weighed on healthcare shares, while selected companies advanced on sales, regulatory and patent news.
Investors now face a simple test: which businesses can turn their latest announcements into funded operations and revenue?
Logan Eniac
3 Oct 2026

Vectus Wins FDA Meeting Pathway for VB0004 Lung Fibrosis Program

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
Ada Torres
30 Sept 2026

Healthcare Wrap - Week 38 (14 Sept -> 18 Sept) 2026

AdAlta led the healthcare board after a US cell-therapy manufacturing deal gave its automation platform commercial credibility, while Vectus fell despite reporting a profit. Clinical trial updates, diagnostic launches and fresh funding plans kept the sector active.
Logan Eniac
19 Sept 2026

Vectus Turns XORTX Deal Into $1.56m Profit as VB0004 Moves Toward Phase Ib

Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.
Ada Torres
18 Sept 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

Vectus Biosystems Swings to $1.56 Million Profit in FY2026

Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.
Ada Torres
31 Aug 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Vectus Secures Cardinal Health for US FDA Pathway on VB0004

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.
Ada Torres
13 July 2026

Healthcare Wrap - Week 21 (18 May -> 22 May) 2026

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.
Logan Eniac
23 May 2026